NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

AC Immune SA (ACIU) Stock Analysis

AC Immune SA (ACIU) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ACIU

$2.86

−$0.07 (−2.39%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ACIU with… →

ACIU Key Statistics

As of Sep 4, 2026
Trading
Open
$2.91
Previous Close
$2.93
Day's Range
2.82–2.94
52-Week Range
2.10–4.00
Volume
155.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.59
Valuation
Market Cap
$284.36M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
4.66
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
16.24
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.52
Financials (FY)
Revenue (FY)
$3.57M−86.92%
Net Income (FY)
−$70.45M
Profit marginThe share of revenue left as profit after all costs and taxes.
−246.48%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
99.43M
1-Year Return
+33.02%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
247.87K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ACIU Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−8.92%
2025+16.30%
2024−46.00%
2023+145.10%
2022−58.79%
2021−4.26%
2020−39.32%
2019−9.84%
2018−26.17%
2017−1.39%
2016 (partial year)−17.11%

As of September 4, 2026.

ACIU Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$3.57M−$70.45M−1971.6%
2024$27.31M−$50.92M−186.4%
2023$14.80M−$54.23M−366.4%
2022$3.94M−$70.75M−1798.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$3.57M—−$68.86M−$70.45M−1971.6%
2024$27.31M—−$52.38M−$50.92M−186.4%
2023$14.80M—−$53.62M−$54.23M−366.4%
2022$3.94M—−$70.85M−$70.75M−1798.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ACIU Valuation vs Biotechnology Median

Median of 656 stocks
MetricACIUBiotechnology medianvs median
P/S ratio16.2415.266% above
Profit margin−246.48%0.00%246.5 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values AC Immune SA (ACIU) at $284.36M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 90.

Over the past 52 weeks the price has ranged from $2.10 to $4.00. The most recent close on file for ACIU is $2.86, dated September 4, 2026. That is −$0.07 (−2.39%) against the previous close. The latest close sits 36.52% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $3.57M. That is −86.92% against the prior fiscal year, when revenue was $27.31M. The same year closed with a net loss of $70.45M. Profit margin runs at −246.48%. That is 246.5 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −0.52.

Across the 4 fiscal years on file, revenue moves from $3.94M in 2022 to $3.57M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 4.66. The price-to-sales ratio is 16.24. On price-to-sales that is 6.4% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +33.02%. Across 10 years the annualized return works out at −15.64%. Beta against the wider market is reported at 1.6. Annualized volatility over the trailing 10 years is 79.14%.

Growth & Income

No dividend is on file for ACIU.

Across the complete calendar years on file, 2023 returned +145.10% and 2022 returned −58.79%. Of the 9 complete calendar years on file, 2 finished higher. 2026 is still running; the price is −8.92% year to date.

Peer Comparison

AC Immune SA (ACIU) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
AC Immune SA ACIU $284.36M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. AC Immune SA has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About AC Immune SA

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Visit website →